NeuroSense Therapeutics Ltd. filings document foreign private issuer disclosures for a clinical biotechnology company developing PrimeC for severe neurodegenerative diseases. Its Form 6-K reports cover clinical and regulatory updates, PrimeC patent protection, scientific publication of PARADIGM trial results, Nasdaq continued-listing notifications, and incorporation of selected reports into Form S-8 and Form F-3 registration statements.
The company’s regulatory record also addresses shareholder voting matters, including amendments to registered share capital, capital-structure disclosures, governance changes, material agreements, operating and financial results, and leadership or advisory arrangements tied to the PrimeC development program.
NeuroSense Therapeutics Ltd. (NRSN) submitted a report stating that it has received FDA clearance to initiate a pivotal phase 3 clinical trial of its lead candidate PrimeC in amyotrophic lateral sclerosis (ALS). The update is provided through a press release furnished as an exhibit and is also incorporated by reference into several of the company’s existing registration statements. The filing itself does not include trial design details, timelines, or financial data, but signals that the program has advanced to a late-stage study under FDA oversight.
NeuroSense Therapeutics Ltd. (NRSN) submitted a Form 6-K as a foreign private issuer, mainly to furnish materials for an upcoming shareholder vote. The filing attaches a Notice and Proxy Statement for a special meeting of shareholders scheduled for December 30, 2025, along with a proxy card that shareholders can use to cast their votes.
The company also states that this Form 6-K is incorporated by reference into its existing shelf and employee benefit registration statements on Form S-8 and Form F-3. This linkage means the information in this report is now legally part of those registration statements, which can be relevant for future securities offerings and equity compensation plans.
NeuroSense Therapeutics Ltd. filed a Form F-3 to register 333,334 ordinary shares for resale by the selling shareholder. These shares were issued in a September 2025 private placement under a purchase agreement. We will not receive any proceeds from sales by the selling shareholder; they bear the sale decisions and receive all proceeds.
As context, the company had 29,550,970 ordinary shares outstanding as of October 27, 2025. The September 2025 private placement priced shares at $1.50 for gross proceeds of approximately $0.5 million. NeuroSense’s ordinary shares and warrants trade on Nasdaq as NRSN and NRSNW; on October 27, 2025, NRSN closed at $1.14. The prospectus permits various sale methods by the selling shareholder and does not obligate any sale.
NeuroSense Therapeutics Ltd. filed a Form 6-K to share new clinical information about its drug candidate PrimeC. The company reports, via an attached press release dated October 6, 2025, that PrimeC produces statistically significant reductions in Alzheimer’s disease biomarkers, which are biological signals linked to Alzheimer’s disease activity. The press release describing these results is furnished as Exhibit 99.1 to this report.
NeuroSense Therapeutics Ltd. reports that it held its Annual General Meeting of Shareholders on September 25, 2025. All resolutions presented at the meeting, as described in the company’s earlier Notice and Proxy Statement furnished on Form 6-K on August 21, 2025, were approved by shareholders. The company also states that this Form 6-K is incorporated by reference into its existing registration statements on Form S-8 and Form F-3, meaning the information in this report becomes part of those securities registration documents.
NeuroSense Therapeutics Ltd. filed a Form 6-K after issuing a press release on its Alzheimer’s program. The company reported that its drug candidate shows early signals of benefit in neurons derived from Alzheimer’s patients, suggesting a potentially encouraging effect at the cellular level, though still at an early research stage.
The company is also using this report to update its existing shelf and equity compensation registration statements. The Form 6-K, including only part of Exhibit 99.1 as specified, is incorporated by reference into NeuroSense’s Form S-8 and multiple Form F-3 registration statements, meaning those SEC documents now formally include the information contained in this submission.
NeuroSense Therapeutics Ltd. reports limited clinical survival outcomes and filing cross-references. In the sample presented, 50% (15 of 30) of participants originally randomized to the investigational treatment PrimeC remain alive, while approximately 7% (1 of 14) of participants originally randomized to placebo remain alive. The report also incorporates references to Form S-8 (File No. 333-262480) and multiple Form F-3 filings (File Nos. 333-269306, 333-260338, 333-283656 and 333-284051) to be part of the report from the submission date, subject to any later superseding documents. The filing is signed by CEO Alon Ben-Noon.
NeuroSense Therapeutics Ltd. submitted a Form 6‑K reporting that certain registration statements (Form S‑8 and multiple Form F‑3 filings) are incorporated by reference. The report attaches a Form of Securities Purchase Agreement dated September 4, 2025 between NeuroSense and the purchaser named on the signature pages, and a Press Release dated September 4, 2025. The filing is signed by Alon Ben‑Noon, Chief Executive Officer.
NeuroSense reported a statistically significant clinical benefit for PrimeC at 18 months. An NfL-adjusted MMRM analysis showed a p=0.03 result, corresponding to a 28% relative difference in decline on the ALS Functional Rating Scale-Revised (ALSFRS-R) favoring patients who received PrimeC from study start versus those who began with placebo and switched to PrimeC after six months. The company states these data underscore the clinical importance of initiating PrimeC early in disease progression.